Fig. 4From: The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDSMean values and change over time of absolute lymphocyte count and CRP, separately in each treatment group. Between-group differences were not statistically significant (p = 0.756 and p = 0.734 for lymphocyte count and CRP, respectively). Group A: 109 exosome particles per dose, group B: 1010 exosome particles per doseBack to article page